Together with novel and specific highly-efficient small molecule inhibitors of the PDE6D-KRAS interaction [9,17,21], this marks a promising therapeutic strategy for HCC and other cancer types [11]. This evidence concerns the gene KRAS and hepatocellular carcinoma.